Numerai’s Revance Therapeutics, Inc. RVNC Stock Holding History

Numerai’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-26,444	Closed	-$488K	–	205
2022 Q4	$488K	Buy	+26,444	New	+$605K	0.33%	83

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Numerai's RVNC Position: Q1 2023 in Review

Numerai sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 26,444 shares — an estimated $488K sold.

Numerai first reported a position in RVNC in Q4 2022 and held it in 1 quarter. The position peaked at $488K in Q4 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

Numerai reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Numerai sold 26,444 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $488K.
Numerai first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 1 quarter.
Numerai's Revance Therapeutics, Inc. position peaked at $488K in Q4 2022.
216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Numerai's 13F filing for Q1 2023, filed 12 May 2023.